Eye Tech Care brings pioneering non-invasive treatment against glaucoma to China
Company is looking to partner with the right distributors and additional capital investors from Asia
[Country Business Reports interviews and articles by Discovery Reports www.discoveryreports.com]
Next to cataract, glaucoma figures as the second source of blindness among patients, according to ophthalmology market reports. Among the 120 million people in the world affected by glaucoma, the highest prevalence is in China with 22 million patients, a number growing at an average of 7.5 per cent annually.
Thanks to the China Food and Drug Administration’s (CFDA) approval of Eye Tech Care’s EyeOP1, the patients in the country are provided with an alternative non-invasive treatment that minimises risks associated with traditional options. With proprietary focused ultrasound technology, this computer-controlled medical device treats glaucoma with easy-to-perform, reproducible, non-operator-dependent therapy that is safely done in three minutes.
“We dedicate a strategy for Asia, particularly in China, to make this device an accepted standard of care for glaucoma,” says Dr Dietrich Wolf, CEO. “The CFDA approval allows good progress to our penetration of the market and the rest of Asia.”
We dedicate a strategy for Asia, particularly in China, to make this device an accepted standard of care for glaucoma
The pioneering French technology has been recognised by the 2016 Europe Frost & Sullivan Award for Technology Innovation, and has treated about 5,000 glaucoma patients around the world since its introduction to the market. Its impressive results and convenient process have leveraged its worldwide success against other technologies for glaucoma treatment.
